1257265-86-3

Basic information

• Product Name: (2R,4S)-5-biphenyl-4-yl-4-[(5-carboxymethylfuran-2-carbonyl)amino]-2-methylpentanoic acid
• Synonyms: (2R,4S)-5-biphenyl-4-yl-4-[(5-carboxymethylfuran-2-carbonyl)amino]-2-methylpentanoic acid
• CAS NO: 1257265-86-3
• Molecular Weight: 435.477
• Mol File: 1257265-86-3.mol

Chemical Properties

• CAS DataBase Reference: (2R,4S)-5-biphenyl-4-yl-4-[(5-carboxymethylfuran-2-carbonyl)amino]-2-methylpentanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,4S)-5-biphenyl-4-yl-4-[(5-carboxymethylfuran-2-carbonyl)amino]-2-methylpentanoic acid(1257265-86-3)
• EPA Substance Registry System: (2R,4S)-5-biphenyl-4-yl-4-[(5-carboxymethylfuran-2-carbonyl)amino]-2-methylpentanoic acid(1257265-86-3)

Safety Data

• Hazardous Substances Data: 1257265-86-3(Hazardous Substances Data)

Upstream product

• 1087784-37-9 5-methoxycarbonylmethyl-furan-2-carboxylic acid methyl ester 
• 1605-20-5 5-carboxymethylfuran-2-carboxylic acid 
• 149690-12-0 (2R,4S)-5-([1,1'-biphenyl]-4-yl)-4-amino-2-methylpentanoic acid ethyl ester hydrochloride 

Relevant articles and documents

METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY

The present invention provides the use of a neutral endopeptidase inhibitor, in the manufacture of a medicament for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The invention also relates to the use of a compound of Formula I: wherein R1, R2, R3, R5, X, A3, B1, s and n are defined herein, for the treatment, amelioration and/or prevention of contrast-induced nephropathy. The present invention further provides a combination of pharmacologically active agents for use in the treatment, amelioration and/or prevention of contrast-induced nephropathy.

SUBSTITUTED AMINOBUTYRIC DERIVATIVES AS NEPRILYSIN INHIBITORS

The present invention provides a compound of formula (I') or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.